Quercetin effectiveness in patients with COVID-19 associated pneumonia

Authors

  • I. A. Zupanets National University of Pharmacy, Kharkiv, Ukraine, Ukraine https://orcid.org/0000-0003-1253-9217
  • O. O. Tarasenko National University of Pharmacy, Kharkiv, Ukraine, Ukraine https://orcid.org/0000-0002-8454-1829
  • N. P. Bezuhla National University of Pharmacy, Kharkiv, Ukraine, Ukraine https://orcid.org/0000-0002-6420-2547
  • M. F. Pasichnyk PJSC SIC “Borshcahivskiy CPP”, Kyiv, Ukraine, Ukraine
  • S. O. Karabynosh Municipal Non-Commercial Enterprise “Regional Clinical Infectious Diseases Hospital” of the Transcarpathian Regional Council, Uzhhorod, Ukraine, Ukraine
  • V. S. Kopcha Ivan Horbachevsky Ternopil National Medical University of the Ministry of Health of Ukraine, Ukraine https://orcid.org/0000-0001-9499-3733
  • L. V. Moroz National Pirogov Memorial Medical University, Vinnytsia, Ukraine, Ukraine https://orcid.org/0000-0002-7111-3155
  • H. V. Maksymchuk Municipal Non-Commercial Enterprise “Central City Hospital” of the Rivne City Council, Rivne, Ukraine, Ukraine
  • O. Ya. Kobrynska Municipal Non-Commercial Enterprise “Central City Clinical Hospital” of the Ivano-Frankivsk City Council, Ivano-Frankivsk, Ukraine, Ukraine
  • R. M. Fishchuk MD, Physician of the Department of ENT Organs Microsurgery, Ukraine
  • D. I. Schulha Municipal Non-Commercial Enterprise “Regional Clinical Infectious Diseases Hospital” of the Kharkiv Regional Council, Kharkiv, Ukraine, Ukraine
  • R. S. Morochkovskyj Municipal Enterprise “Volyn Regional Infectious Diseases Hospital” of the Volyn Regional Council, Lutsk, Ukraine, Ukraine
  • M. S. Zoshchak Municipal Non-Commercial Enterprise “Irpin Central City Hospital” of the Irpin City Council of the Kyiv region, Ukraine, Ukraine

DOI:

https://doi.org/10.14739/2310-1210.2021.5.231714

Keywords:

quercetin, pneumonia, COVID-19, treatment

Abstract

The aim of this work was to evaluate the effectiveness of quercetin addition to the treatment regimen for patients with COVID-19 associated pneumonia.

Materials and methods. The effectiveness of two dosage forms of quercetin was studied in 200 patients, who were divided equally into the main and control groups. The main group patients received quercetin in addition to the basic therapy: intravenous drip of Quercetin/Polyvinylirolidone during the first 10 days followed by oral administration of Quercetin/Pectin over the next 10 days. Patients from the control group received only the basic therapy drugs.

The study evaluated the dynamics of the disease symptoms (saturation level, respiratory rate, body temperature, cough, general weakness), as well as laboratory markers (C-reactive protein (CRP), ferritin, D-dimer).

Results. Two dosage forms of quercetin consistently used in addition to the basic therapy improve pulmonary gas exchange and accelerate the lung function recovery. This is evidenced by a statistically significant majority of patients with positive dynamics in the symptoms of “Saturation level” and “Cough” as well as the meeting a complex indicator of the therapy effectiveness 2 days earlier than in the control group. The treatment regimen applied also helps to stabilize the level of D-dimer in the blood of the main group patients.

Conclusions. The use of two dosage forms of quercetin in addition to the basic therapy accelerates the recovery of patients with coronavirus disease associated pneumonia and can help to prevent the progression of COVID-19 associated coagulopathy.

Author Biographies

I. A. Zupanets, National University of Pharmacy, Kharkiv, Ukraine

MD, PhD, DSc, Professor of the Department of Clinical Pharmacology and Clinical Pharmacy

О. А. Holubovska, Bogomolets National Medical University, Kyiv, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Infectious Diseases

O. O. Tarasenko, National University of Pharmacy, Kharkiv, Ukraine

MD, PhD, Associate Professor of the Department of Clinical Pharmacology and Clinical Pharmacy

N. P. Bezuhla, National University of Pharmacy, Kharkiv, Ukraine

MD, PhD, Associate Professor of the Department of Clinical Pharmacology and Clinical Pharmacy

M. F. Pasichnyk, PJSC SIC “Borshcahivskiy CPP”, Kyiv, Ukraine

PhD, General Director

S. O. Karabynosh, Municipal Non-Commercial Enterprise “Regional Clinical Infectious Diseases Hospital” of the Transcarpathian Regional Council, Uzhhorod, Ukraine

MD, Infectious Disease Physician of the Department for Adults

V. S. Kopcha, Ivan Horbachevsky Ternopil National Medical University of the Ministry of Health of Ukraine

MD, PhD, DSc, Professor of the Department of Infectious Diseases with Epidemiology, Skin and Venereal Diseases

L. V. Moroz, National Pirogov Memorial Medical University, Vinnytsia, Ukraine

MD, PhD, DSc, Professor of the Department of Infectious Diseases with Epidemiology

H. V. Maksymchuk, Municipal Non-Commercial Enterprise “Central City Hospital” of the Rivne City Council, Rivne, Ukraine

MD, Head of the Infectious Diseases Department

O. Ya. Kobrynska, Municipal Non-Commercial Enterprise “Central City Clinical Hospital” of the Ivano-Frankivsk City Council, Ivano-Frankivsk, Ukraine

MD, Physician of Therapeutic Department No. 1

R. M. Fishchuk, MD, Physician of the Department of ENT Organs Microsurgery

MD, Physician of the Department of ENT Organs Microsurgery

D. I. Schulha, Municipal Non-Commercial Enterprise “Regional Clinical Infectious Diseases Hospital” of the Kharkiv Regional Council, Kharkiv, Ukraine

MD, Infectious Disease Physicianof the Department No. 1

R. S. Morochkovskyj, Municipal Enterprise “Volyn Regional Infectious Diseases Hospital” of the Volyn Regional Council, Lutsk, Ukraine

MD, Head of the Department for Adult Patients

M. S. Zoshchak, Municipal Non-Commercial Enterprise “Irpin Central City Hospital” of the Irpin City Council of the Kyiv region, Ukraine

MD, Infectious Disease Physician of the Infectious Diseases Department

References

World Health Organization. (2021, April 20). Weekly epidemiological update on COVID-19 - 20 April 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-april-2021

FDA. (2020, October 22). FDA Approves First Treatment for COVID-19. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19

Singh, B., Ryan, H., Kredo, T., Chaplin, M., & Fletcher, T. (2021). Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database of Systematic Reviews, 2(2), Article CD013587. https://doi.org/10.1002/14651858.CD013587.pub2

Metlay, J. P., & Waterer, G. W. (2020). Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Annals of Internal Medicine, 173(4), 304-305. https://doi.org/10.7326/M20-2189

Griffiths, M., McAuley, D. F., Perkins, G. D., Barrett, N., Blackwood, B., Boyle, A., Chee, N., Connolly, B., Dark, P., Finney, S., Salam, A., Silversides, J., Tarmey, N., Wise, M. P., & Baudouin, S. V. (2019). Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respiratory Research, 6(1), Article e000420. https://doi.org/10.1136/bmjresp-2019-000420

Ascierto, P. A., Fu, B., & Wei, H. (2021). IL-6 modulation for COVID-19: the right patients at the right time? Journal for ImmunoTherapy of Cancer, 9(4), Article e002285. https://doi.org/10.1136/jitc-2020-002285

Ozgen, S., Kilinc, O. K., & Selamoğlu, Z. (2016). Antioxidant Activity of Quercetin: A Mechanistic Review. Turkish Journal of Agriculture - Food Science and Technology, 4(12), 1134-1138. https://doi.org/10.24925/turjaf.v4i12.1134-1138.1069

Zhang, M., Swarts, S. G., Yin, L., Liu, C., Tian, Y., Cao, Y., Swarts, M., Yang, S., Zhang, S. B., Zhang, K., Ju, S., Olek, D. J., Schwartz, L., Keng, P. C., Howell, R., Zhang, L., & Okunieff, P. (2011). Antioxidant Properties of Quercetin. In J. LaManna, M. Puchowicz, K. Xu, D. Harrison, & D. Bruley (Eds.). Oxygen Transport to Tissue XXXII (Vol. 701, pp. 283-289). Springer US. https://doi.org/10.1007/978-1-4419-7756-4_38

Xiao, X., Shi, D., Liu, L., Wang, J., Xie, X., Kang, T., & Deng, W. (2011). Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis through Inactivation of P300 Signaling. PLOS ONE, 6(8), Article e22934. https://doi.org/10.1371/journal.pone.0022934

Shebeko, S. K., Zupanets, I. A., Popov, O. S., Tarasenko, O. O., & Shalamay, A. S. (2018). Chapter 27 - Effects of Quercetin and Its Combinations on Health. In R. R. Watson, V. R. Preedy, & S. Zibadi (Eds.), Polyphenols: Mechanisms of Action in Human Health and Disease (2nd ed., pp. 373-394). Academic Press. https://doi.org/10.1016/B978-0-12-813006-3.00027-1

Marik, P. (2020, May 5). EVMS critical care COVID-19 management protocol. EVMS Medical Group. https://www.sbk-vs.de/images/pdf/downloads/Corona/EVMS_Critical_Care_COVID-19_Protocol.pdf?m=1606470173&

Usenko, V. F., Zupanets, I. A., Tarasenko, O. O., & Shebeko, S. K. (2012). Eksperymentalne doslidzhennia farmakokinetychnykh vlastyvostei kvertsetynu pry peroralnomu zastosuvanni z modyfikatoramy rozchynnosti [Experimental study of pharmacokinetic properties of quercetin at oral apрlication with modifiers of solubility]. Medychna i klinichna khimiia, 14(1), 91-95. [in Ukrainian].

Parkhomenko, A. N., & Kozhukhov, S. N. (2014). Rezul’taty otkrytogo randomizirovannogo issledovaniya po izucheniyu perenosimosti i effektivnosti preparata Korvitin® u patsientov s zastoinoi serdechnoi nedostatochnost’yu i sistolicheskoi disfunktsiei levogo zheludochka [The results of an open randomized study to investigate the tolerability and efficacy of Corvitin® in patients with congestive heart failure and left ventricular systolic dysfunction]. Ukrainskyi medychnyi chasopys, (4), 71-76. [in Russian].

Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020). Endothelial cell infection and endotheliitis in COVID-19. The Lancet, 395(10234), 1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5

Chornomydz, I. B. (2011). Kliniko-patohenetychne obgruntuvannia zastosuvannia kvertsytynu u kompleksnomu likuvanni ditei iz hostroiu pozalikarnianoiu pnevmoniieiu [Clinical and nosotropic ground of application of quercetin in complex treatment of children with acute extrahospital pneumonia]. Visnyk naukovykh doslidzhen, (1), 34-36. [in Ukrainian].

Fedortsiv, O. Ye., Chornomydz, I. B., & Behosh, N. B. (2013). Klinichna efektyvnist vykorystannia kvertsetynu u kompleksnomu likuvanni ditei, khvorykh na pozalikarnianu pnevmoniiu [Clinical efficiency quercetin in complex treatment of children with community-acquired pneumonia]. Aktualni pytannia pediatrii, akusherstva ta hinekolohii, (2), 7-9. [in Ukrainian].

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3

Published

2021-09-01

How to Cite

1.
Zupanets IA, Holubovska ОА, Tarasenko OO, Bezuhla NP, Pasichnyk MF, Karabynosh SO, Kopcha VS, Moroz LV, Maksymchuk HV, Kobrynska OY, Fishchuk RM, Schulha DI, Morochkovskyj RS, Zoshchak MS. Quercetin effectiveness in patients with COVID-19 associated pneumonia. Zaporozhye medical journal [Internet]. 2021Sep.1 [cited 2024Feb.24];23(5):636-43. Available from: http://zmj.zsmu.edu.ua/article/view/231714

Issue

Section

Original research